In contrast, PCa patients with high UHRF1 levels could benefit from more extensive monitoring, such as ultrasound-guided biopsy, computed tomography, magnetic resonance imaging, and bone scans. This evidence concerns the gene UHRF1 and posterior cortical atrophy.